Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System.
Inoue Y, Okamoto H, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Kaneko H, Kuwahara-Ota S, Fuchida SI, Nishiyama D, Hirakawa K, Uchiyama H, Uoshima N, Kawata E, Kuroda J. Inoue Y, et al. Among authors: nishiyama d. Oncol Lett. 2023 Dec 18;27(2):62. doi: 10.3892/ol.2023.14193. eCollection 2024 Feb. Oncol Lett. 2023. PMID: 38192677 Free PMC article.
Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.
Okamoto H, Inoue Y, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Kaneko H, Kuwahara-Ota S, Fuchida SI, Nishiyama D, Hirakawa K, Uchiyama H, Uoshima N, Kawata E, Kuroda J; KOTOSG investigators. Okamoto H, et al. Among authors: nishiyama d. Int J Hematol. 2023 Sep;118(3):323-332. doi: 10.1007/s12185-023-03627-6. Epub 2023 Jun 28. Int J Hematol. 2023. PMID: 37378717
Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti-SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms.
Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, Nishiyama D, Shimura K, Kaneko H, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J. Onishi A, et al. Among authors: nishiyama d. Infect Drug Resist. 2023 Jan 25;16:509-519. doi: 10.2147/IDR.S396271. eCollection 2023. Infect Drug Resist. 2023. PMID: 36721633 Free PMC article.
Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.
Onishi A, Matsumura-Kimoto Y, Mizutani S, Isa R, Fujino T, Tsukamoto T, Miyashita A, Okumura K, Nishiyama D, Hirakawa K, Shimura K, Kaneko H, Kiyota M, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Onishi A, et al. Among authors: nishiyama d. Int J Hematol. 2024 Jan;119(1):50-61. doi: 10.1007/s12185-023-03680-1. Epub 2023 Dec 12. Int J Hematol. 2024. PMID: 38082201
Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.
Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Chinen Y, Tanba K, Kuwahara-Ota S, Fujibayashi Y, Nishiyama D, Isa R, Yamaguchi J, Kawaji-Kanayama Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Matsumura-Kimoto Y, et al. Among authors: nishiyama d. Cancer Med. 2020 Jul;9(14):5185-5199. doi: 10.1002/cam4.3136. Epub 2020 May 18. Cancer Med. 2020. PMID: 32420699 Free PMC article.
A novel method of amplified fluorescent in situ hybridization for detection of chromosomal microdeletions in B cell lymphoma.
Mizuno Y, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Matsumura-Kimoto Y, Fujibayashi Y, Kuwahara-Ota S, Fujino T, Nishiyama D, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Mizuno Y, et al. Among authors: nishiyama d. Int J Hematol. 2019 May;109(5):593-602. doi: 10.1007/s12185-019-02617-x. Epub 2019 Mar 4. Int J Hematol. 2019. PMID: 30830578
Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.
Yamaguchi J, Fujino T, Isa R, Nishiyama D, Kuwahara-Ota S, Kawaji Y, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Kohno K, Nakamura S, Kuroda J. Yamaguchi J, et al. Among authors: nishiyama d. Haematologica. 2019 Aug;104(8):e376-e379. doi: 10.3324/haematol.2019.217141. Epub 2019 Apr 11. Haematologica. 2019. PMID: 30975907 Free PMC article. No abstract available.
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Kuwahara-Ota S, Shimura Y, Steinebach C, Isa R, Yamaguchi J, Nishiyama D, Fujibayashi Y, Takimoto-Shimomura T, Mizuno Y, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Kobayashi T, Horiike S, Taniwaki M, Gütschow M, Kuroda J. Kuwahara-Ota S, et al. Among authors: nishiyama d. Br J Haematol. 2020 Dec;191(5):784-795. doi: 10.1111/bjh.16881. Epub 2020 Jun 19. Br J Haematol. 2020. PMID: 32558939 Free article.
Toward further simplification of elotuzumab therapy by subcutaneous administration.
Shimura Y, Tsukamoto T, Yamaguchi J, Kuwahara-Ota S, Isa R, Nishiyama D, Kobayashi T, Horiike S, Suzuki A, Kuroda J. Shimura Y, et al. Among authors: nishiyama d. Int J Hematol. 2020 Sep;112(3):427-428. doi: 10.1007/s12185-020-02942-6. Epub 2020 Jul 13. Int J Hematol. 2020. PMID: 32656639 No abstract available.
38 results